中晚期肝癌化学免疫治疗与单纯TAE治疗疗效比较

Comparison of the Effects with Chemo-Immunotherapy and TAE on Mid-Advanced Hepatocellular Carcinoma

本文采用肝动脉化学栓塞(TAE)后1～2周内行LAK/IL2的化学免疫治疗(Chemo-immu-notherapy CIT)中晚期肝癌(Mid-advanced HCC)42例(CIT组),TAE治疗2 7例为对照(TAE组)。结果:Ⅱ期HCC 2年生存率47.4％,Ⅱ期HCC部分缓解率(PR)和3个月、半年、1年生存率分别为39.1％、73.9％、56.5％和34.7％,显著高于TAE组Ⅱ期HCC二年生存率16.7％,(P<0.05)和Ⅱ期HCC部分缓解率为6.7％,三个月、半年、1年生存率40.0％,13.3％和6.7％,P<0.05;Ⅱ期HCC 1年内肝外转移率(25.5％)明显低于TAE组(66.7％,P<0.05)。表明化学免疫治疗能显著提高中晚期肝癌疗效。

The comparison of effects with chemo- immunotherapy (CIT) using LAK/ IL after 1～2 weeks of TAE and TAE in the treatment of mid advanced HCC were reported. Forty-two patients had been treated by CIT (CIT group) and twenty-seven by TAE (TAE group) served as for controll were studied. The mean survial times were 21.5 and 9.6 months respectively in stage, Ⅱ, Ⅲ of HCC, significantly longer than that of TAE (14.3 and 3.4 months respectively, P<0.05). 2 years survival rate in stage II and 3, 6, 12 months survial rates in stage III were 47.4%, 73.9%, 56.5% and 34.7% respectively, significantly higher than those of the controll group (16.7%, 40.0%, 13.3% and 6.7% respectively, P<0.05). The partial remmision (PR) rate was 39.1% in stage III HCC, significantly higher than that in TAE group (6.7%, P<0.05), The results showed chemo- immunotherapy was more favorable for mid-advanced HCC.